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Wild type chicken gizzard caldesmon (756 amino acids) was expressed in a T7 RNA polymerase-based bacterial expression system at a yield of 
1 mg pure caldesmon per litre bacterial culture. A mutant composed of amino acids l-578 was also constructed and expressed. The wild type 
and mutant caldesmon were purified and compared with native chicken gizzard caldesmon. Native and wild type expressed caldesmon were indistin- 
guishable in assays for inhibition of actin-tropomyosin activation of myosin ATPase, reversal of inhibition by Caz+-cahnodulin and binding to 
actin, actin-tropomyosin, Ca2+-calmodulin, tropomyosin and myosin. The mutant missing the C-terminal 178 amino acids had no inhibitory effect 
and did not bind to actin or Ca*+-calmodulin. It bound to tropomyosin with a 5-fold reduced affinity and to myosin with a greater than IO-fold 
reduced affinity. 
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1. INTRODUCTION 
Caldesmon is an actin binding protein present in 
smooth muscle and non-muscle cells. In smooth mus- 
cle, caldesmon is specifically located on the thin 
filaments within the contractile domain [1,2]. In vitro, 
caldesmon binds to actin, tropomyosin, calcium bin- 
ding proteins such as calmodulin, SlOO and troponin C 
[3-51 and to smooth muscle myosin [6]. Caldesmon is a 
potent inhibitor of actin-tropomyosin activation of 
myosin ATPase activity and this inhibition is reversed 
by Ca2 + and calcium binding proteins [3]. These obser- 
vations suggest hat caldesmon may provide a calcium- 
sensitive thin filament-based means of regulation of 
smooth muscle contractility, complementary to that 
provided by the reversible phosphorylation of the 
myosin regulatory light chain. Caldesmon may also be 
involved in the formation of the ‘latch bridge’ in 
smooth muscle via reversible attachment to myosin 
[6,7], thus cross-linking the thick and thin filaments. 
mains to a 40 kDa C-terminal chymotryptic fragment 
while the myosin binding site has been localised towards 
the N-terminus [&lo]. The cloning and sequencing of a 
caldesmon cDNA encoding 756 amino acids from a 
chicken gizzard library has recently been reported [ 111. 
As a first step towards localising more precisely the 
functional regions of caldesmon we have expressed this 
cDNA in a bacterial expression system and produced 
wild type caldesmon and a mutant encoding the first 
578 amino acids. We have developed a method for the 
purification of milligram quantities of these expressed 
proteins and compared their activities with those of the 
native protein purified from chicken gizzard in a range 
of in vitro assays. 
2. MATERIALS AND METHODS 
2.1. Expression 
Proteolytic cleavage of caldesmon has localised its in- 
hibitory activity and actin and calmodulin binding do- 
The full length chicken gizzard CDM57 sequence [!I] and a 
NcoI/DraI fragment encoding the N-terminal 578 amino acids were 
subcloned into a T7 RNA polymerase-based xpression vector derived 
from the PET vector [12] (gift from Dr. M. Way, LMB, Cambridge). 
BL21 (DE3) cells containing the additional plasmid pLysE were used 
for expression as previously described [ll] and induced cells were 
harvested by centrifugation. 
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2.2. Purification 
Abbreviations: DTT, dithiothreitol; EDTA, ethylenediaminetetra- 
acetic acid; EGTA, ethyleneglycol-bis-(-aminoethyl 
ether)N,N,N’,N’-tetraacetic acid; PIPES, piperazine-N,N’-bis-2- 
ethanesulphonic acid; SDS-PAGE, sodium dodecyl sulphate 
polyacrylamide electrophoresis; TAME, p-tosyl-L-arginine methyl 
ester; TPCK, N-tosyl-L-phenylalanine chloromethyl ketone 
Cell pellets were resuspended in 25% sucrose, 50 mM Tris-HC!, 2 
mM EGTA, 2 mM EDTA, 2 mM DTT, pH 8.0, in the presence of 10 
Cg/ml each of soy bean trypsin inhibitor, TAME and TPCK. The cells 
were lysed with lysozyme and treated with DNAseI [13]. Sodium 
chloride was added to 600 mM and the lysed cells were heated to boil- 
ing in a microwave oven and then rapidly cooled. After centrifugation 
at 36 000 x g for 20 min the supernatant was taken and the pH 
lowered to 4.0. The solution was centrifuged (36 000 x g, 10 mitt) and 
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the pellet which contained the caldesmon was resuspended in minimal 
volume. Final purification of caldesmon was by gel filtration on 
Sephacryl S300 in 25 mM Tris-HCl, 200 mM NaCl, 2 mM EDTA, 1 
mM MgClz, 2 mM DTT pH 7.5. Caldesmon-containing fractions 
were pooled and concentrated by precipitation in 50% ammonium 
sulphate. Both the wild type and mutant proteins were purified by this 
method. 
2.3. Purification of native proteins 
Chicken gizzard caldesmon was prepared by a variation of 
Bretscher’s technique [14] described in [15]. Sheep aorta tropo- 
myosin, F-actin and thiophosphorylated myosin were prepared as in 
our previous work [3,16]. Skeletal muscle myosin and bovine brain 
calmodulin were prepared by standard techniques [17,181. 
3. RESULTS 
3.1. Expression of caldesmon 
Using the full length chicken gizzard caldesmon 
cDNA, CDM57 [I 11, a low level of expression of 
caldesmon was obtained. The protein was identified by 
SDS-PAGE (Fig. 1) and on Western blots using an anti- 
chicken gizzard caldesmon antiserum. Expressed wild 
type caldesmon comprised less than 1% of total cell 
protein after induction; a similar level of protein was 
obtained using the mutant NcoI/DraI construct. Cen- 
trifugation of boiled, lysed cells yielded a supernatant 
enriched in caldesmon (Fig. 1, lane b) which was con- 
centrated with some further purification by isoelectric 
precipitation at pH 4.0 (Fig. 1, lane c). Final purifica- 
tion was achieved by gel filtration on Sephacryl S300 
(Fig. 1, lane d). The yield was approximately 1 mg/l of 
bacterial culture; a similar yield and purity was obtain- 
ed with the mutant (Fig. 1, lane e). The wild type was 
expressed as the full 756 amino acids plus a Met-Gly-Ser 
N-terminal fusion peptide while the mutant had the 
same N-terminal tripeptide, amino acids l-578 of 
caldesmon plus a Pro-Leu-Val C-terminal fusion pep- 
tide. 
3.2. Functional properties of native and expressed 
caldesmon 
Native and wild type caldesmon inhibited the actin- 
tropomyosin activation of skeletal muscle myosin 
ATPase with similar potencies (Fig. 2). The same 
results were obtained with both skeletal and smooth 
muscle actins. The inhibition of skeletal muscle actin- 
sheep aorta tropomyosin activation of myosin ATPase 
by both native and wild type caldesmon was reversed by 
high concentrations of Ca’ + -calmodulin (Fig. 2, inset). 
Wild type and native caldesmon bound to actin (Fig. 
3) or actin-tropomyosin with the same relative affinity. 
A similar level of binding by both native and wild type 
caldesmon to Ca2 + -calmodulin was detected by non- 
dissociating gel electrophoresis [5]. Caldesmon-tropo- 
myosin binding was assayed by monitoring the fluor- 
escence of pyrene maleimide-labelled tropomyosin 
which is enhanced up to 50% by caldesmon binding 
[19]. Native and wild type caldesmon bound to tropo- 
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Fig. 1. 5-20% gradient polyacrylamide, 0.1 Vo SDS gel electrophoresis 
stained with Coomassie Blue. Lanes: (a) total protein from induced 
cells carrying the full length caldesmon construct (10 pg); (b) superna- 
tant following heating and centrifugation (1 cg); (c) pH 4.0 pellet 
(1 gg); (d) purified wild type caldesmon after Sephacryl S300 gel 
filtration (1 rg); (e) purified mutant (1 yg); (f) purified native chicken 
gizzard caldesmon (1 pg). M = molecular weight markers. 
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Fig. 2. Inhibition of actin-tropomyosin activated myosin ATPase by 
caldesmon and its reversal by Ca’+-calmodulin (inset). Legend: 
(-o-), native; (-•--), wild type; (-A -), mutant caldesmon. 
Rates were measured at 25°C by our standard method [3] using 0.125 
mg/ml skeletal muscle myosin, 0.5 mg/ml actin, 0.2 mg/ml 
tropomyosin and caldesmon/actin molar ratios of between 0 and 0.34 
in 5 mM Kz * PIPES, 60 mM KCI, 5 mM MgClz, 1 mM DTT pH 7.0. 
The reversal of inhibition (inset) was measured using 0.22 
caldesmon/skeletal muscle actin and 0, 30 and 80 FM 
Ca* ’ -calmodulin. 
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Fig. 3. Cosedimentation of caldesmon with aorta F-actin. Legend as 
in Fig. 2. 1 CM caldesmon was mixed with O-36 CM actin in ATPase 
buffer. F-actin was pelleted in an airfuge and the supernatants were 
analysed by SDS-PAGE. The caldesmon bands were quantified by 
Fig. 5. Cosedimentation of caldesmon with aorta myosin. Legend as 
in Fig. 2. 1 CM caldesmon was mixed with O-5 CM thiophosphorylated 
smooth muscle myosin in 5 mM K2 . PIPES, 2.5 mM MgC12, 1 mM 
DTT pH 7.0. Myosin filaments were pelleted in an airfuge and the 
supernatants analysed by SDS-PAGE. The caldesmon bands were 
quantified by scanning densitometry. 
scanning densitometry. 3.3. Functional properties of mutant caldesmon 
myosin with the same apparent binding constant of 
around 2 x lo6 M-l (Fig. 4). Caldesmon binding to 
smooth muscle myosin was determined by cosedimenta- 
tion at low ionic strength (Fig. 5); native and wild type 
caldesmon showed essentially identical binding proper- 
ties with affinities greater than lo6 M-i. 
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Fig. 4. Effect of caldesmon on pyrene-tropomyosin fluorescence. 
Legend as in Fig. 2. 0.5 pM tropomyosin labelled with N-(l-pyrenyl)- 
maleimide [19] was mixed with O-4 FM caldesmon in 5 mM 
K1. PIPES, 40 mM KCl, 5 mM MgClz, 1 mM DTT pH 7.0. 
Fluorescence mission peaks at 377 nm were measured after excitation 
at 340 nm in a Perkin-Elmer fluorescence spectrophotometer (model 
LS-5). Data are expressed as Vo increase compared with pyrene- 
tropomyosin alone. 
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Measurements were made on 4 preparations. The 
mutant caldesmon did not alter actin-tropomyosin ac- 
tivation of myosin ATPase (Fig. 2), it did not bind to 
actin (Fig. 3) and exhibited weak binding to actin- 
tropomyosin (10% of 1 PM caldesmon cosedimented 
with 40 pM actin-tropomyosin). There was significant 
binding of the mutant to tropomyosin (Fig. 4) and to 
smooth muscle myosin (Fig. 5) but the affinities were 
significantly reduced compared with the wild type, 5- 
fold for tropomyosin binding and > IO-fold for myosin 
binding. 
4. DISCUSSION 
4.1. Expression of wild type and mutant caldesmon 
The level of expression of both the wild type and mu- 
tant caldesmon was at least one order of magnitude 
lower than that achieved with certain other proteins, 
e.g. gelsolin and myosin light chain (Dr. M. Way and T. 
Rowe respectively, LMB, Cambridge, personal com- 
munication) using the same expression system. The 
level is however higher than that achieved using the 
same construct in BL21(DE3) cells without pLysE and 
higher than that obtained using the pLcII/QY 13 system 
of Nagai and Thogersen [ 131 (data not shown and [ 1 I]). 
Despite the poor expression the use of large volumes of 
culture and the development of a simple purification 
procedure which exploited the heat and acid stability of 
caldesmon yielded sufficient pure protein to make 
quantitative measurements of caldesmon function in 
biochemical assays. On SDS-PAGE the expressed wild 
type protein comigrated with native caldesmon with an 
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apparent molecular weight of 120 000 [5] while the mu- 
tant showed an apparent molecular weight of 100 000 
(Fig. 1). Both apparent molecular weights were con- 
siderably higher than their molecular weights calculated 
from their sequence [ 111, 87 000 and 68 000 respec- 
tively. 
4.2. Expressed wild type caldesmon is fully functional 
Whilst the expression of small amounts of caldesmon 
has been reported [11,20] only a few properties have 
been examined in non-quantitative assays. We have 
now shown that wild type expressed caldesmon is essen- 
tially identical to native caldesmon in quantitative 
assays of inhibition of actin-tropomyosin activation of 
myosin ATPase and reversal by Ca2 + -calmodulin (Fig. 
2, [3]), binding to actin and actin-tropomyosin (Fig. 3, 
[3]), smooth muscle myosin (Fig. 5), tropomyosin (Fig. 
4, [19]) and calmodulin [5]. These results indicate that 
caldesmon expressed in a bacterial cell refolds into its 
native state and remains stable under the harsh condi- 
tions used for its subsequent purification (95°C [14], 
pH 3 [3]). Thus the ability of caldesmon to refold into 
a fully functional state allows one to express mutants 
and test their functional properties. 
4.3. Properties of mutant caldesmon (amino acids 1 to 
578) 
The expressed mutant caldesmon containing amino 
acids 1 to 578 was found to be unable to bind to actin 
or Ca’ + -calmodulin or to inhibit actin-tropomyosin ac- 
tivated myosin ATPase; however, it did retain the abili- 
ty to bind to tropomyosin although the affinity was 
diminished about 5-fold. Actin and calmodulin binding 
have been localised in a C-terminal 15 000 to 20 000 
proteolytic fragment of caldesmon [S-11] which is ab- 
sent from the mutant. The mutant does contain the se- 
quence 508-565 which has been identified as a potential 
tropomyosin binding site on the basis of homology with 
the tropomyosin binding site of troponin T [ 11,201. The 
weak tropomyosin binding indicates either that the mu- 
tant contains some but not all of the residues responsi- 
ble for tropomyosin binding or that the deletion of the 
178 residues affected the folding in the remainder of the 
protein, causing the reduced affinity for tropomyosin. 
The mutant binds poorly to smooth muscle myosin; 
this contradicts previous results [lo,211 obtained using 
myosin affinity columns which have indicated that 
there is a discrete myosin binding site within the first 
200 amino acids from the N-terminus of caldesmon; 
however, both the results with tropomyosin and myosin 
binding are in agreement with Katayama et al. [22] who 
reported that full binding to these two proteins required 
the presence of the C-terminal 40K fragment. 
Since the wild type expressed caldesmon is in- 
distinguishable from native caldesmon, this expression 
system will be of great use in relating structure to func- 
tion of caldesmon and is potentially much more ver- 
satile than current work using proteolytically or 
chemically fragmented native caldesmon. Although we 
have so far looked at only one mutant caldesmon we 
have already been able to confirm the gross predictions 
from previous work and show that the precise 
dependence of function on structure is likely to be 
rather more complex than previously suggested. 
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